Article Abstract

A new rat model of prostate cancer

Authors: Robert Rees


The current status of immunotherapy of cancer dictates that tumour cells should express appropriate antigenic peptides on the cell surface associated with MHC class I antigen. Therapies designed to activate immunity against cell surface expressed target peptides are required to induce antigen specific cytotoxic T-lymphocytes (CTL) capable of mediating tumour rejection and that such immune responses should produce immunological memory. The necessity for both MHC class I (CTL response) and class II (T-helper response) - restricted responses has been well documented and the nature of tumour antigens expressed on a wide variety of human cancers widely reported.